Responses
Regular and young investigator award abstracts
Clinical trials completed
286 Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4–1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer
Compose a Response to This Article
Other responses
No responses have been published for this article.
